Quarterly report pursuant to Section 13 or 15(d)

Stockholders' Deficit (Details Narrative)

v3.19.3
Stockholders' Deficit (Details Narrative) - USD ($)
 1 Months Ended 3 Months Ended 12 Months Ended
Jul. 23, 2018
Jul. 20, 2018
Sep. 30, 2017
Mar. 31, 2019
Mar. 31, 2018
Dec. 31, 2018
Sep. 18, 2018
Common stock shares authorized       10,000,000,000   10,000,000,000 10,000,000,000
Common stock par value       $ 0.0001   $ 0.0001 $ 0.0001
Preferred stock shares authorized       5,000,000     5,000,000
Preferred stock par value       $ 0.01     $ 0.01
Number of common stock issued, value          
Common stock shares issued       3,503,882,657   128,567,273  
Common stock shares outstanding       3,503,882,657   128,567,273  
Recognized stock stock-based compensation       $ 8,650 665,307    
Interest expense       4,100,000      
2007 Equity Plan [Member]              
Stock option expense       $ 8,649 $ 24,196    
Weighted average period       7 years      
Intrinsic value of options exercisable       $ 0      
Employees and Directors [Member] | Restricted Stock [Member]              
Number of restricted stock issued         142,667    
Recognized stock stock-based compensation         $ 477,933    
Stock issued price per share         $ 3.35    
Common Stock [Member]              
Number of common stock issued       119,615,384 151,200    
Number of common stock issued, value       $ 11,961 $ 15    
Cashless exercise warrants       755,000,000      
Number of shares converted       3,255,700,000   106,335,991  
Number of restricted stock issued         142,667    
Warrants [Member]              
Number of warrants issued as anti-dilution provision       582,000,000,000      
Series G Preferred Stock [Member]              
Preferred stock shares authorized       14,000   14,000  
Preferred stock par value       $ 0.01   $ 0.01  
Preferred stock shares outstanding       215   215  
Preferred stock, stated value       $ 1,000      
Weighted average common stock price percentage       85.00%      
Series H Preferred Stock [Member]              
Preferred stock shares authorized       14,202   14,202  
Preferred stock par value       $ 0.01   $ 0.01  
Preferred stock shares outstanding       10   10  
Preferred stock, stated value       $ 1,000      
Weighted average common stock price percentage       85.00%      
Series F Convertible Preferred Stock [Member]              
Preferred stock shares outstanding       1,750,000      
Series F Convertible Preferred Stock [Member] | Genomas, Inc [Member]              
Number of common stock issued     1,750,000        
Number of common stock issued, value     $ 174,097        
Stock conversion share price     $ 14,625        
Conversion of stock into shares     120        
Preferred stock price per share for unpaid dividend     $ 1.95        
Series J Convertible Preferred Stock [Member]              
Preferred stock shares outstanding       250,000      
Number of common stock issued   250,000          
Series J Convertible Preferred Stock [Member] | Alcimede LLC [Member]              
Preferred stock, stated value $ 1.00            
Number of common stock issued 250,000            
Number of common stock issued, value $ 250,000            
Cumulative dividends percentage 8.00%            
Series I-2 Preferred Stock [Member]              
Number of shares converted       547.298   1,286.141